U.S. markets closed

  • S&P 500

    3,509.44
    -1.01 (-0.03%)
     

  • Dow 30

    28,323.40
    -66.78 (-0.24%)
     

  • Nasdaq

    11,895.23
    +4.30 (+0.04%)
     

  • Russell 2000

    1,644.16
    -15.89 (-0.96%)
     

  • Crude Oil

    37.49
    -1.30 (-3.35%)
     

  • Gold

    1,951.50
    +4.70 (+0.24%)
     

  • Silver

    25.70
    +0.51 (+2.04%)
     

  • EUR/USD

    1.1879
    +0.0053 (+0.45%)
     

  • 10-Yr Bond

    0.8200
    +0.0440 (+5.67%)
     

  • GBP/USD

    1.3150
    +0.0002 (+0.01%)
     

  • USD/JPY

    103.3600
    -0.2400 (-0.23%)
     

  • BTC-USD

    15,035.25
    +22.71 (+0.15%)
     

  • CMC Crypto 200

    302.63
    +5.06 (+1.70%)
     

  • FTSE 100

    5,910.02
    +3.84 (+0.07%)
     

  • Nikkei 225

    24,325.23
    +219.95 (+0.91%)
     

Earnings Update: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Simply Wall St
·3 min read

It's been a good week for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shareholders, because the company has just released its latest third-quarter results, and the shares gained 6.3% to US$131. Revenues of US$126m beat expectations by a respectable 5.7%, although statutory losses per share increased. Alnylam Pharmaceuticals lost US$2.18, which was 33% more than what the analysts had included in their models. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

View our latest analysis for Alnylam Pharmaceuticals

earnings-and-revenue-growth
earnings-and-revenue-growth

After the latest results, the 20 analysts covering Alnylam Pharmaceuticals are now predicting revenues of US$803.4m in 2021. If met, this would reflect a huge 100% improvement in sales compared to the last 12 months. The loss per share is expected to greatly reduce in the near future, narrowing 33% to US$5.22. Before this latest report, the consensus had been expecting revenues of US$835.2m and US$4.82 per share in losses. So it's pretty clear consensus is more negative on Alnylam Pharmaceuticals after the new consensus numbers; while the analysts trimmed their revenue estimates, they also administered a per-share loss expectations.

There was no major change to the consensus price target of US$163, signalling that the business is performing roughly in line with expectations, despite lower earnings per share forecasts. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. Currently, the most bullish analyst values Alnylam Pharmaceuticals at US$225 per share, while the most bearish prices it at US$90.00. Note the wide gap in analyst price targets? This implies to us that there is a fairly broad range of possible scenarios for the underlying business.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. The analysts are definitely expecting Alnylam Pharmaceuticals' growth to accelerate, with the forecast 100% growth ranking favourably alongside historical growth of 47% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 20% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that Alnylam Pharmaceuticals is expected to grow much faster than its industry.

The Bottom Line

The most important thing to take away is that the analysts increased their loss per share estimates for next year. Regrettably, they also downgraded their revenue estimates, but the latest forecasts still imply the business will grow faster than the wider industry. The consensus price target held steady at US$163, with the latest estimates not enough to have an impact on their price targets.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have forecasts for Alnylam Pharmaceuticals going out to 2024, and you can see them free on our platform here.

And what about risks? Every company has them, and we've spotted 1 warning sign for Alnylam Pharmaceuticals you should know about.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.

Latest Stories

  • How a Biden presidency could change your tax bill

    A victory by Democratic presidential candidate Joe Biden in the November election could significantly change tax bills for a slew of Americans. Here's what you need to know.

  • Stock Market Rally Wins In Landslide, Nvidia In Buy Range; Do This Before Monday's Open

    The market rally is showing real power on election results, with several top stocks in buy range. Do this before Monday's opening bell.

  • Cramer Gives His Opinion On Workhorse, Alibaba And More

    On CNBC's "Mad Money Lightning Round," Jim Cramer said he would pick First Solar Inc. (NASDAQ: FSLR) over Solaredge Technologies Inc. (NASDAQ: SEDG).Plantronics Inc. (NYSE: PLT) is a good company and a very high quality stock, he said. He prefers lower-end companies, more gaming oriented, but he doesn't want to go against the call and he thinks Plantronics is a good one.Workhorse Group Inc. (NASDAQ: WKHS) is a bit of a showhorse for Cramer. If he wanted an EV stock, he would buy Plug Power Inc. (NASDAQ: PLUG).Instead of Moneygram International Inc. (NASDAQ: MGI), Jim Cramer would buy Paypal Holdings Inc. (NASDAQ: PYPL) because it is going all in with crypto.Fortinet Inc. (NASDAQ: FTNT) is okay, Cramer said. He prefers Palo Alto Networks Inc. (NYSE: PANW) and Crowdstrike Holdings Inc. (NASDAQ: CRWD). Cramer is pounding the table to buy Alibaba Group Holding Ltd. (NYSE: BABA).Trupanion Inc. (NASDAQ: TRUP) also is good, Cramer said -- he thinks we need pet insurance.See more from Benzinga * Click here for options trades from Benzinga * Carter Worth And Mike Khouw See SLV Moving Higher * Tony Zhang Sees Bullish Sign For American Water Works(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Here’s what a President Joe Biden would mean for Americans’ retirement savings

    Of course, retirement security was on some legislators’ minds before the election. The Ways and Means Committee introduced bipartisan legislation last month called the Securing a Strong Retirement Act of 2020, which builds upon the Secure Act passed in December.

  • Warren Buffett Doubles Down On Major Reversal In Investing Strategy

    Warren Buffett jumped back into the stock market again in Q3, after net selling in Q2, and spent a record amount buying back Berkshire Hathaway shares.

  • Here’s what a Biden presidency spells for stocks, bonds and commodities

    After days on tenterhooks, investors now have clarity about the next occupant of the White House and will start planning for the presidency of Joe Biden.

  • Oil Stocks – Buying Opportunity of a Lifetime

    I do not see how we can have inflation without much higher energy prices. Consequently, I am betting big on an energy comeback.

  • What a Joe Biden administration will mean for the economy and markets

    After four days of counting, Joe Biden has been called the victor of the 2020 presidential election, according to the Associated Press.

  • Biogen Bombs at the FDA Panel; J.P. Morgan Weighs In

    By a vote of one for, eight against, and two abstaining, the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee concluded Friday that positive clinical data from Biogen's (BIIB) "EMERGE" trial, when "viewed independently and without regard for" data from the company's "ENGAGE" trial, were not sufficient to convince it that aducanumab is an effective treatment for Alzheimer's.The Advisory Committee furthermore voted zero to seven (with four abstentions) against a finding that Biogen's PRIME study data was any better. And although on the bright side, the committee voted five-to-zero-to-six sort of in favor of the verdict that Biogen has "presented strong evidence of a pharmacodynamic effect of aducanumab on Alzheimer’s disease pathophysiology," in the end, they concluded by a crushing zero-to-10 margin (with one abstention) that it was not reasonable to rely upon the EMERGE data as a reason to approve the drug for commercial sale.That's the bad news.The good news is that the Advisory Committee's recommendations above are not binding on the FDA itself, and the FDA could, therefore, end up approving the drug anyway. (The FDA intends to render its own final verdict by March 7, 2021).But the other bad news is that, when you get right down to it, the Advisory Committee's conclusions were "overwhelmingly negative," as J.P. Morgan analyst Cory Kasimov opined in a note out today. Tallying up the results, points out Kasimov, Biogen garnered a grand total of just "one yet vote across the three key efficacy questions." And this, in the analyst's opinion, "certainly calls into serious question the FDA's very positive stance on aducanumab."Calling the Advisory Committee's verdicts a "near unanimous vote against aducanumab and strong commentary against the FDA's own analyses," Kasimov warns that "with the FDA's reputation already in a precarious position, it could be difficult -- maybe impossible -- to go against an expert panel at this time no matter how badly they want this."Which kind of makes the March 7 decision sound like a foregone conclusion, and not one that favors Biogen.So what does this mean for Biogen and the investors who've placed their faith in it? On the one hand, the aducanumab polls were unqualifiedly bad for Biogen. Still, they apparently weren't quite bad enough to shake JP Morgan's faith in the company so as to necessitate downgrading the stock from "neutral" (the stock's current rating) to "sell." Nor did Kasimov cut his price target on the stock from its present level of $269 per share.That being said, when you consider that Biogen stock costs nearly $329 a share today, Kasimov's $269 price target does still imply that Biogen stock is worth nearly 19% less than what investors are currently paying for it. (To watch Kasimov's track record, click here)This stock has attracted plenty of interest from Wall Street’s analysts. BIIB’s analyst consensus rating is a Moderate Buy based on 27 reviews, which include 11 Buys against 14 Holds and 2 Sells. (See BIIB stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

  • Biden plans to raise taxes, but would stay out of most individual Americans’ pockets

    Biden won't raise taxes for anyone earning less than $400,000. His plan calls for corporations and the wealthy to pay more.

  • Toyota boss hits out at Tesla

    Toyota’s boss has taken a swipe at Tesla, predicting Elon Musk’s electric car company will lose out to established motor manufacturers as they catch up in battery vehicles. Akio Toyoda, grandson of Toyota’s founder, warned not to dismiss the automotive industry’s giants as his company posted quarterly results which included doubling its full-year profit forecast. “Tesla says that their recipe will be the standard in the future, but what Toyota has is a real kitchen and a real chef,” said Mr Toyoda in a reference to Tesla’s hopes its technologies will become widely adopted. “They aren’t really making something that’s real - people are just buying the recipe,” he added. “We have the kitchen and chef, and we make real food. "When it comes to products, we have a full menu that will be chosen by customers.”

  • These Are The 5 Best Stocks To Buy And Watch Now

    Buying a stock is easy, but buying the right stock without a time-tested strategy is incredibly hard. So what are the best stocks to buy now or put on a watchlist?

  • How much do you really need to save for retirement?

    Here's how to figure it out, with the help of some durable rules of thumb.

  • Analysts Say These 3 Stocks Are Their Top Picks for 2021

    The year is winding down, and most of us would say ‘good riddance.’ Is there evidence that the markets are getting back onto an upward track? The summer saw big gains on Wall Street, perhaps a bubble, but definitely a bull market. September saw it slip off track, October has seen a partial recovery, while November started with a bang — or to be more precise, a boom.Some of Wall Street’s analysts see the remaining time for some smart stock plays in a volatile environment, and they are tagging their top picks to start the new year on a high note. Let's take a closer look.SVB Financial Group (SIVB)The first stock on the list is Silicon Valley’s largest deposit holding bank. SVB Financial Group is the holding company owning Silicon Valley Bank, a commercial bank specializing in high-tech venture capital. Since its founding in the 1980s, SVB has provided funding for more than 30,000 start-ups, and has also become a major financial services provider for Napa Valley’s vineyards.Working in the high-wealth areas of the San Francisco Bay region, and maintaining offices in other financial centers around the world – London, Hong Kong, and Toronto, among others – Silicon Valley Bank was well-positioned to weather the corona crisis. The bank’s revenue has been rising through 2020, from $807 million in Q1, to $860 million in Q2, to $1.08 billion in Q3. Earnings, after a sequential slip entering Q1, have also been on an upward track; the Q3 EPS came in at $8.47, beating the forecast by 55%.The bank’s shares have reflected the strong financial performance. SVB is up 27% year-to-date, having bounced back from the mid-winter market crash.Covering SIVB for Maxim, analyst Michael Diana writes, “SIVB remains our top bank pick due to: 1) its unique, non-replicable franchise; and 2) the growth implications of that franchise… The environment for VC-backed companies has improved, in our view, especially for the technology and life sciences companies that are SIVB's focus… we expect that SIVB's deposits, loan volumes, and investment/warrant gains should all benefit in 2021.”Diana rates SIVB as a Buy, and his $335 price target implies another 10% gain for the year ahead. (To watch Diana’s track record, click here)Overall, SVB Holdings has a Moderate Buy rating from the analyst consensus, based on 13 recent reviews, including 10 Buys, 2 Holds, and 1 Sell. (See SIVB stock analysis on TipRanks)Danaher Corporation (DHR)The second stock on the list is a conglomerate, a globally diversified company based in Washington, DC. Danaher works in the science and technology field, bringing together a range of companies through acquisitions and partnerships. Danaher operates three business segments, Life Sciences, Diagnostics, and Environmental & Applied Solutions.Danaher has performed well through 2020, repeating its normal pattern of rising earnings from Q1 – but on steroids. The first quarter EPS was low, at $1.05, but quickly rose to $1.44 in Q2 and then $1.72 in Q3. The third quarter result was 25% higher than expectations. Revenues followed a similar path, gaining from $4.3 billion in Q1 to $5.9 billion in Q3.DHR shares have heavily outperformed the overall markets this year, rising nearly 60%.Doug Schenkel, 5-star analyst from Cowen, sees Danaher benefitting directly from the current pandemic situation and, as a result, moves the stock to a Top Pick.“We believe DHR has one of the best product portfolios among the Tools group to address the current COVID-19 challenges (bioprocessing, Dx). Over the next several quarters, a double-digit pro forma core revenue growth rate appears attainable, in part driven by these COVID-19 solutions. Looking beyond the current pandemic, we believe management commentary on the evolution of the business portfolio, strategy to extract durable revenue from near-term COVID-19 driven demand, and M&A capacity (we estimate ~$15B+ over the next 12 months) should help build confidence that DHR is now plausibly built to generate sustainable HSD core revenue growth. This would be an impressive growth profile for a nearly ~$200B market cap Tools company and is well above current consensus estimates.” Schenkel opined. Schenkel, who is rated 56 of more than 7,000 analysts in the TipRanks database, rates DHR shares as an Outperform (i.e. Buy). His price target of $275 indicates an upside of 12% in the next 12 months. (To watch Schenkel’s track record, click here)Overall, Danaher boasts a Strong Buy analyst consensus rating, and it is unanimous – the stock has received 6 Buys in recent weeks. (See DHR stock analysis on TipRanks)Boston Beer (SAM)The last stock on the list today is one you may be familiar with. Boston Beer is the owner of Sam Adams, the popular brew named after the Colonial-era patriot. Boston Beer is the fourth largest brewery in the US, boasted $1.33 billion in revenue for 2019.So far, 2020 has been a good year for Boston Beer. To put it bluntly, the social lockdown policies keeping people at home caused many of them to turn to beer for comfort, and Boston Beer has a well-liked flagship brand. The company’s earnings have risen steadily this year, from $1.32 in Q1 to $6.10 in Q3. At the top line, revenues have moved from $330 million in the first quarter, to $492 million in the third.Of the stocks on this list, Boston Beer has shown the strongest year-to-date share appreciation. The stock has almost tripled, gaining 183% despite all the vicissitudes of 2020.Cowen analyst Vivien Azer, who holds 5 stars with TipRanks, has reviewed the company's latest Q3 results and was duly impressed. As a result, Azer reiterated SAM as her Top Pick.“SAM handily beat our above-consensus est. for 3Q (historically their biggest EPS quarter, at 40% of 2019)… the company expects *all* of their brands to grow in 2021… Despite the reality of COVID uncertainty, select nuances inform the company's ahead-of-expectation outlook: 1) delayed shelf sets… 2) line of sight in terms of in-house and outsourced capacity and 3) an outlook for a doubling of hard seltzer,” Azer wrote.In line with her upbeat outlook, Azer rates the stock as a Buy along with a $1,250 price target. Her target suggests an upside of 17% over the coming year. (To watch Azer’s track record, click here)Overall, SAM shares get a Moderate Buy rating from the analyst consensus on Wall Street. The stock has 9 recent reviews, breaking down to 6 Buys and 3 Holds. (See SAM stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

  • 7 Best Marijuana Stocks to Buy

    The election results are bullish for marijuana stocks. Cannabis stock investors didn't get the blue wave they were hoping for in the U.S. election, but all five state marijuana legalization measures on the ballot have passed. Recreational and/or medical marijuana was legalized in Arizona, Mississippi, Montana, New Jersey and South Dakota, increasing the potential geographic footprint of cannabis multistate operators, or MSOs.

  • 10 Best-Performing 401(k) Funds

    The 401(k) might be the best wealth-building tool for retirement ever created. Couple the ongoing tax savings with the best 401(k) funds, and average investors can find a path to financial security. When it comes to options, a company's provider determines what 401(k) mutual funds are available.

  • 5 of the Best Tech Stocks to Buy for November

    With earnings season well underway, Wall Street now has its eyes firmly affixed on the 2020 elections. One of those Big Tech names that has been under scrutiny from Congress, Facebook shares popped on Nov. 4, as investors breathed a sigh of relief that Capitol Hill would likely be divided.

  • Thiel-Backed Palantir Soars as Biden Inches Closer to Win

    (Bloomberg) -- Palantir Technologies Inc. surged on Friday on speculation that Democrat Joe Biden -- nearing victory in the U.S. presidential race -- would rein in military spending and spur demand for the company’s lower-priced surveillance technology.The stock rose as much as 26%, the most since its direct listing in September as many investors expect defense spending would be cut under a Biden administration.Palantir, which was co-founded by Peter Thiel, counts the U.S. Defense Department among its largest customers and could benefit from budget cuts because its software often costs less than similar offerings from traditional defense contractors.Its shares could also be benefiting from short sellers exiting their positions as the stock rises, according to Melius Research analyst Carter Copeland, who called the stock’s volatility “stunning.”“Given that the rest of the defense and industrial security complex hasn’t reacted in the same way, one would conclude there’s an element of short covering here,” he said in an interview.About 6% of Palantir shares that are available to trade are being sold short, according to the latest data from financial analytics firm S3 Partners. That’s down from about 9% on Oct. 28.Palantir has now gained about 32% since the U.S. election was held on Nov. 3, adding more than $5 billion in market value. The company is scheduled to report financial results for the first time as a publicly traded company on Nov. 12.(Adds context to first paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • The Deck’s Stacked Against Exxon Mobil, So Stay Away

    2020 has meant a perfect storm of headwinds for Exxon Mobil (NYSE:XOM). First, of course, the novel coronavirus pandemic. I don’t have to tell you why the virus, and the resultant “stay at home economy,” has decimated demand for crude oil. In turn, it has also meant big losses for XOM stock. Source: Jonathan Weiss / Shutterstock.com But, that’s not all! In addition, this year has also brought a major pivot toward “clean energy.” We know that full well from the strong performance of electric vehicle (EV) and other “green wave” stocks. Topping it all off is the contentious 2020 U.S. presidential election. As of this writing, the results are still pending. Yet, former Vice President Joe Biden, who vowed to “transition” us away from oil, is just a few electoral votes away from securing victory.InvestorPlace - Stock Market News, Stock Advice & Trading Tips All together, this is bad news for big oil. With all these negative factors at play, it’s no surprise Exxon shares remain near multi-decade lows. But even at today’s prices (around $33.15 per share), shares could head even lower from here. 7 Unicorn Startups to Watch Into 2021 Beyond the pandemic and the election, long-term economic and political changes are not in its favor. The result? A continued reversal of fortune for this once-venerable blue-chip stock. XOM Stock Has Multiple Hurdles to Jump Post-election, is the worst priced into Exxon’s beaten-down shares? Not exactly. The bear case goes beyond who ends up winning the presidency. That is to say, even if incumbent President Donald Trump manages to win the remaining states up for grabs and secure re-election, it won’t make a difference. Even with a president more friendly to big oil, the demographic and economic factors pivoting us to the “green economy” are moving forward. As I discussed last week, millennials and Generation Z are more concerned with environmental issues. The oldest millennials are pushing forty and moving into positions of economic and political power. Coupled with Generation Z coming of age, it’s clear “green” policies are no longer on the political fringe. All of this plays into the continued growth of EVs. Sensing the shift, the entire automotive industry is adapting to this megatrend. Sure, we’ll still have internal combustion vehicles a decade from now, but as the EV share of the overall auto market continues to climb, expect crude oil prices to remain depressed. And if oil can’t get out of its current rut, expect Exxon Mobil to remain “stuck in neutral” — or even worse — as well. Don’t Let High Yield Cloud Your Judgement The underlying trends don’t bode well for XOM stock. But despite these terrible prospects, some investors may still be tempted to dive into this stock that’s fast falling out of favor. Why? Some could see it as a great contrarian play. Yet, there’s a difference between going contrarian on a stock and trying to catch a falling knife. Simply put, you have to read the room. The winds of change are blowing in the wrong direction for Exxon Mobil stock. But it’s not just contrarian investors who may be interested in this hard-hit, once venerable blue-chip. The high dividend yield (10.49%) of XOM stock may be another factor that’s enticing misguided investors. In a low-interest environment, this is catnip for those searching for yield. But again, you have to read the room. There’s good reason why Wall Street has priced Exxon Mobil shares to the point where its dividend is in the double-digits. This fat yield isn’t coming out of profit. Right now, the company is generating losses. To sustain its current high payout (and keep its 38-year streak of dividend growth going), the company is borrowing heavily to avoid a dividend cut. This strategy may work in the near term, but if this continues, something’s got to give. Some sort of dividend freeze or cut is inevitable. If this happens, expect shares to fall further. The dividend is one of the few things shoring up its current share price. Without it, the investor exodus out of this blue-chip will continue. Bottom Line: Exxon Isn’t Coming Back, So Steer Clear Sure, the near-term headwinds hammering this stock could subside. The economic environment could improve, if and when the pandemic recedes. Joe Biden’s remarks about big oil could wind up being all talk and no action, with minimal short-term changes to U.S. energy policy. Yet, the long-term factors working against Exxon remain in motion. As millennials and Generation Z gain more economic and political power, and the unstoppable growth of EVs continues, expect a further shift toward a “green” economy. With these factors more than countering its tempting dividend and record low prices, the answer’s clear: stay away from XOM stock. On the date of publication, neither Matt McCall nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article. Matthew McCall left Wall Street to actually help investors — by getting them into the world’s biggest, most revolutionary trends BEFORE anyone else. Click here to see what Matt has up his sleeve now.   More From InvestorPlace Why Everyone Is Investing in 5G All WRONG Top Stock Picker Reveals His Next 1,000% Winner Radical New Battery Could Dismantle Oil Markets Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company Daily Picks: Stocks to Buy Ahead of the Election The post The Deck’s Stacked Against Exxon Mobil, So Stay Away appeared first on InvestorPlace.

  • Why Cramer Says A Biden Win Is Bullish For Rocket Companies

    On Thursday's "Mad Money" show, host Jim Cramer highlighted Rocket Companies as a good stock to own in response to a caller.Cramer On Rocket Companies: The caller asked Cramer's thoughts on Rocket Companies Inc (NYSE: RKT) going into earnings next week.The caller said they bought shares in the $17 to $18 range and believe the increased mortgage numbers will help with earnings.Cramer said Rocket Companies is a "very well-run company."The Detroit-based mortgage lenders are "much better lenders than traditional lenders in terms of defaults," the CNBC host said. Cramer's catalysts for the stock are low interest rates, an exodus of people moving from the city to the suburbs and a Joe Biden win in the presidential race. "There's going to be a wave of immigration," he said. Related Link: Rocket Mortgage, Mint Partner On Refinancing Tech: What Investors Should KnowWhat's Next: Rocket Companies will report quarterly earnings on Nov. 10 after the market close."This might be a perfect stock to own," Cramer said.RKT Price Action: Shares of Rocket Companies were up 1.72% at $21.31 the close Friday. Shares have traded between $17.50 and $34.42 since going public earlier this year.See more from Benzinga * Click here for options trades from Benzinga * A Rocket Companies Subsidiary Acquires Fast-Growing Canadian Mortgage Platform Finmo(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.